Amtagvi
(Lifileucel)Phase 3Cell therapy
This medication is a personalized cancer treatment made from your own immune cells. It is used to treat melanoma (a type of skin cancer) that has spread to other parts of the body or cannot be surgically removed and hasn't responded to other treatments. The drug works by boosting your body's natural immune system to attack and destroy cancer cells.[1] Amtagvi is currently being investigated across 6 indications[3], with its most advanced program in Phase 3.[1]
Amtagvi is one of 156 biologic programs targeting Metastatic Melanoma. It is currently in Phase 3.
6
Indications
11
Total Trials
9
Active Trials
155
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
191 competitors in Melanoma
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Cotellic
RochePhase 3
Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Mektovi
PfizerPhase 3
Tecentriq
RochePhase 3
Libtayo
RegeneronPhase 3
Intron a
Merck & Co.Phase 3
Fabhalta
RegeneronPhase 3
Paraplatin
AAvyxa
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metastatic Melanoma4 trials
Melanoma2 trials
Endometrial Cancer1 trial
Tumor Infiltrating Lymphocytes1 trial
Uveal Melanoma1 trial
2 more indications
Melanoma, Cutaneous Malignant1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lifileucel. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 3[1]
- Company
- IIovance Biotherapeutics, Inc.